Tenderwize
Back to tender search

Open House Discount Contracts for Ranibizumab (Vial)

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 226 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ranibizumab, als Durchstechflasche, ATC S01LA04

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

25 / 100

Risk factors

The buyer reserves the right to replace open-house contracts with exclusive contracts from EU tenders, which would auto...

As an open-house model, there is no guaranteed purchase volume or spend; contracts are purely discount agreements.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Provision of non-exclusive discount contracts for the active substance Ranibizumab (ATC S01LA04) as a vial.
  • Contracts are open to all interested pharmaceutical companies meeting the eligibility criteria.
Show full summary

This is an open-house model for non-exclusive discount contracts (Rabattverträge) for the pharmaceutical product Ranibizumab (ATC S01LA04) as a vial, offered by AOK Rheinland-Pfalz/Saarland. The contract period is from 01.06.2025 to 31.05.2027, with the possibility to join at any month start. The first submission deadline for the initial contract start is 30.04.2025. No estimated value is provided. This is not a classic procurement but a voluntary transparency publication.

Risks

The buyer reserves the right to replace open-house contracts with exclusive contracts from EU tenders, which would auto...

As an open-house model, there is no guaranteed purchase volume or spend; contracts are purely discount agreements.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Pharmaceutical company must offer authorized and marketable drugs in Germany.

Administrative

  • Drugs must be listed in the Lauer-Taxe as marketable; otherwise, evidence from AMIce database or other documentation is required.
  • Submission of signed contract documents by specified deadlines.

Requirements may be incomplete.

Buyer

Lots (1)

LOT-0001

Open House Discount Contracts for Ranibizumab (Vial)

Non-exclusive discount contracts for Ranibizumab (ATC S01LA04) as a vial. Maximum contract duration 24 months from 01.06.2025 to 31.05.2027. First contract conclusion possible on 01.06.2025. All contracts end at the latest 24 months after the earliest start date. Open to all interested pharmaceutical companies offering authorized and marketable drugs in Germany.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Deadline

Expired Apr 30, 2025

Procurement Details

Publication date
10 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
236800-2025

Documents (1)

Similar tenders